Survey Reveals Majority of Patients Diagnosed with Chronic Pulmonary Disorders Are Unaware of Standard-of-Care Treatment for Their Deadly Disease Chronic respiratory diseases – primarily COPD – are the third leading cause of death, yet 62 percent of patients have not heard of pulmonary rehabilitation NEW YORK, Nov. 12, 2018 (GLOBE NEWSWIRE)...

Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired Bacterial Pneumonia at the American Thoracic Society Conference CHAPEL HILL, N.C., May 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...

FDA Chooses Four CPF Advocates to Speak on IPF Workshop Panel DISTRICT OF COLUMBIA, Wash., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Four of the eight panelist to address the FDA tomorrow at the first U.S. Food and Drug Administration (FDA) workshop on Idiopathic...

September Most Important Month in History for U.S. Patients Suffering from Idiopathic Pulmonary Fibrosis: FDA Workshop, Impending Drug Decisions, PF Month Activities CULVER CITY, Calif., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Never before have there been so many opportunities for patients to be heard regarding a deadly lung disease than this month: the U.S. Food and...